Johan Albrecht
Analyst · Lake Street Capital
Thank you, Fried. I'll begin with a brief review of our consolidated revenue on Slide 7. As a reminder, when we refer to sales in our presentation, we mean revenues plus deferred revenues. Also, please note that unless otherwise stated, comparisons in this call are against our results for the third quarter of 2020. Revenue was EUR52.2 million for the quarter, 28% above the level over the same period last year. The growth took place in all 3 segments, our software and medical segments grew by 10%, our revenue in manufacturing bounced back by 61%. Deferred revenues from software license and maintenance fees increased by EUR0.5 million compared to the end of last year. For the third quarter of 2021, Materialise software accounted for 20% of our total revenue, Materialise manufacturing for 36% and Materialise manufacturing or 44%. Cross-segment revenue from software products represented 31% of our total revenue. Moving to Slide 8. You will see our consolidated adjusted EBITDA numbers for the third quarter of 2021. Consolidated adjusted EBITDA grew to a new quarterly record of EUR9,739,000 from EUR6 million last year. Our revenue grew 28%, EBITDA grew 62%. This increase was a result of a variety of positive factors. Our strong revenue growth and improved gross margin triggered by increased in-sourcing and continuous productivity improvements and disciplined spending, in particular with respect to overhead. Importantly, the increase of our EBITDA did not come at the expense of our R&D spending, which actually increased by 13% compared to last year. In addition, the initiatives we previously described to enhance our internal business application platform continued and are on track. Slide 9 summarizes the results of our Materialise software segment. Software revenue increased 10.4% to EUR10,468,000. But recurrence revenue was flat, non-recurring revenue grew 33.6%, driven by new perpetual license and compliance fees. EBITDA increased 19% to EUR3.7 million, and the adjusted EBITDA margin grew to 35.4%. This is a result of the solid revenue growth and our operating expenses kept well under control even as efforts in R&D and in our digital transformation project continued. Moving now to Slide 10. You will see that total revenue in our Materialise medical segment increased by 10.2% to EUR18.9 million. Revenue from medical software sales grew 15%, where revenue from medical devices and services increased 8.5% compared to last year. Revenue from medical software sales accounted for 31% of segment revenue. Adjusted EBITDA amounted to EUR5,251,000 compared to EUR5.5 million last year. This quarter's adjusted EBITDA was negatively impacted by EUR800,000 with respect to an accrual for the litigation that originated in 2014, related to which we received the court decision this quarter. Excluding the non-recurring expenditure, the segment's adjusted EBITDA margin was 31.8% at the same high level as last year. This was a combined result of continued top line growth, production efficiency improvements, in-sourcing programs and containment of operating expenses. This all while we accelerated the execution of our R&D programs and continued our digital transformation project. Now let's turn to Slide 11 for an overview of the Q3 performance of our Materialise manufacturing segment. Revenue increased 61.2% or EUR8.7 million to EUR22.8 million. Importantly, revenue was approximately at the Q2 level and EUR3.7 million higher than in the first quarter of this year when we first noted the positive signs from segments that had it hard during the corona period in 2020. Adjusted EBITDA for the quarter rose EUR3.9 million to EUR3.5 million. The adjusted EBITDA margin grew to 15.5% as a result of the revenue growth, optimized capacity usage and improved production efficiencies. The EBITDA was positively affected by a one-time fee of $900,000 that we received in the framework of the winding down of our partnership with Ditto. Slide 12 provides the highlights of our income statement for the third quarter. Gross profit increased 33.4% to EUR31.1 million, while the gross profit margin grew to 59.5% from 57.1% last year. The solid margin was due to the increased revenue, the higher level of capacity usage and productivity improvement in all of our segments. Operating expenses increased 11.3% compared to last year's quarter, but part of our remuneration costs were saved through various government support programs. Our sales and marketing spending increased 12.7%. G&A expenditures increased 8%, and R&D expenses grew 12.6%. This quarter's net operating income was EUR355,000 compared to EUR1.2 million last year. As a result of these elements, the group's operating results grew EUR4.2 million to EUR4,529,000 compared to EUR284,000 in last year's period. Our financial net income was positive EUR4.2 million compared to a net cost of EUR1.3 million in the previous year. This quarter's results included a positive EUR3.7 million effect from recovering our borrowings positions, including interest from Ditto and positive currency exchange gains of EUR1.2 million, mainly from a dollar position we maintained from our June and July public offering proceeds. The third quarter of 2021 contained income tax expenses of EUR80,000 compared to a tax income of EUR764,000 in the third quarter of 2020. The profit for Q3 increased to a quarterly record of EUR8,652,000 compared to a net loss of EUR282,000 for the 2020 period. For the first time, the company's history reported earnings of EUR0.15 per share. Now please turn to Slide 12 for a recap of balance sheet and cash flow highlights. In July 2021, our balance sheet was further strengthened by the net capital increase of EUR11.4 million from the issuance of 600,000 additional new shares following the exercise of the underwriter's option to purchase additional shares in connection with the public offering of 4 million shares issued in June 2021. At September 30, our cash amounted to EUR194.9 million compared to EUR111.5 million at the end of last year, whereas in this, while our borrowings position decreased by EUR12.9 million to EUR102.2 million, only EUR21 million of our debt was short-term at September 30. Our net cash position further improved this quarter to EUR92.8 million. Equity increased EUR95.4 million to EUR228.5 million as a combined result of the capital increase of EUR85.8 million. The first nine months net profit amounting to EUR8.4 million and positive conversion differences of EUR1.1 million. Total deferred revenue amounted to EUR35 million. Of this amount, EUR30.8 million was related to annual software sales and maintenance contracts purchased at EUR30.2 million as of December 31, 2020. Cash flow from operating activities for the first nine months of 2021 were EUR17.5 million compared to EUR14.8 million in 2020. Capital expenditures for the quarter amounted to EUR3.3 million and were not financed. Peter?